Alexandria Real Estate Equities, Inc. Celebrates 20 Years of Prix Galien USA and More than Two Decades of Investing in and Catalyzing Life Science Innovation in New York City
Key Highlights
- ➤MAP-D completed its design phase in June 2026 and began advancing toward a longitudinal depression study
- ➤AVI participated in Nilo Therapeutics' oversubscribed $101 million Series A financing in October 2025
- ➤Eikon Therapeutics completed an upsized $381 million IPO in February 2026
- ➤Intra-Cellular Therapies achieved a $14.6 billion Johnson & Johnson acquisition in 2025
- ➤Alexandria celebrates 20 years of Prix Galien USA partnership and NYC life science investment
Expert Statements
Joel S. Marcus, Executive chairman and founder of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
“For 20 years, the Prix Galien USA has recognized outstanding scientific achievements that have changed the course of human health, and Alexandria is deeply proud of our founding partnership with the Galien Foundation and our shared commitment to advancing life-changing innovation”
Joel S. Marcus, Executive chairman and founder of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
“Driven by our noble mission to advance human health, Alexandria Venture Investments (AVI) is the second most active institutional life science investor in NYC, providing strategic capital and expertise to companies pursuing novel approaches across oncology, neuroscience, gene therapy and AI-enabled drug discovery.”
Alexandria Real Estate Equities, Inc. Celebrates 20 Years of Prix Galien USA and More than Two Decades of Investing in and Catalyzing Life Science Innovation in New York City PR Newswire
PASADENA, Calif., Oct. 29, 2026 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, longest-tenured and pioneering owner, operator and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation clusters, today celebrates the 20th anniversary of the Prix Galien USA in New York City and its longstanding strategic partnership with the Galien Foundation, a premier global organization dedicated to recognizing and advancing scientific innovation that improves human health. For more than two decades, Alexandria has been a driving force in the creation and growth of New York City's commercial life science ecosystem, bringing together mission-critical infrastructure, strategic venture capital and world-class talent to catalyze and grow innovative life science companies.
Get started
Create a free account to read the full story.